MDCLF (Medincell) Price-to-Operating-Cash-Flow: (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDCLF Medincell SA MDCLF
77 GF Score
Price $34.39
GF Value $27.51
! 5 Warning Signs
View Full Analysis

What is Medincell Price-to-Operating-Cash-Flow?

As of today (2026-07-14), Medincell's share price is $34.39. Medincell's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.84. Hence, Medincell's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Medincell's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 11 years, Medincell's highest Price-to-Operating-Cash-Flow Ratio was 58.54. The lowest was 19.54. And the median was 31.65.

MDCLF's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 21.625
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Medincell's Cash Flow from Operations per share for the six months ended in Mar. 2026 was $-0.31. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.84.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Medincell was -204.10% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 6.40% per year.

During the past 11 years, Medincell's highest 3-Year average Operating Cash Flow per Share Growth Rate was 8.70% per year. The lowest was -38.50% per year. And the median was -3.90% per year.

Medincell Price-to-Operating-Cash-Flow Historical Data

* Premium members only.

The historical data trend for Medincell's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medincell Price-to-Operating-Cash-Flow Chart

Medincell Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 21.92 0.00

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 21.92 0.00 0.00

MDCLF vs VRTX, REGN, ALNY: Price-to-Operating-Cash-Flow Comparison

For the Biotechnology subindustry, Medincell's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell Price-to-Operating-Cash-Flow vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Medincell's Price-to-Operating-Cash-Flow falls into.


MDCLF
77GF Score
Medincell SA MDCLF
Price-to-Operating-Cash-Flow is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medincell Price-to-Operating-Cash-Flow Calculation

Medincell's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=34.39/-0.839
=

Medincell's Share Price of today is $34.39.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medincell's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.84.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Is Medincell (MDCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.

Key valuation signals for MDCLF:

  • Price-to-Operating-Cash-Flow:
  • GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score

Get the complete analysis for MDCLF

Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.39
Price
$27.51
GF Value